Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

@article{Kantarjian2007UpdateOT,
  title={Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome},
  author={H. Kantarjian and S. O'brien and J. Shan and Ahmed Aribi and G. Garcia-Manero and E. Jabbour and F. Ravandi and J. Cortes and J. Davisson and J. Issa},
  journal={Cancer},
  year={2007},
  volume={109}
}
  • H. Kantarjian, S. O'brien, +7 authors J. Issa
  • Published 2007
  • Medicine
  • Cancer
  • Therapy for patients with myelodysplastic syndrome (MDS) with hypomethylating agents, like decitabine and 5‐azacitidine, has produced favorable results. In this study, the authors update their experience with decitabine in patients with MDS and analyze the cytogenetic response patterns and prognostic factors associated with decitabine therapy. 
    An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
    • 39
    • Open Access

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 24 REFERENCES
    Decitabine improves patient outcomes in myelodysplastic syndromes
    • 1,216
    • Open Access
    The myelodysplastic syndromes.
    • 888
    International scoring system for evaluating prognosis in myelodysplastic syndromes.
    • 3,793
    • Open Access